US 11,654,106 B2
Aqueous suspension suitable for oral administration
Sandip P. Mehta, Ahmedabad (IN); Henil Alpeshbhai Patel, Ahmedabad (IN); and Jayanta Kumar Mandal, Ahmedabad (IN)
Assigned to LIQMEDS WORLDWIDE LIMITED, Hayes (GB)
Filed by LIQMEDS WORLDWIDE LIMITED, Middlesex (GB)
Filed on May 26, 2022, as Appl. No. 17/824,993.
Application 17/824,993 is a continuation of application No. 16/308,731, granted, now 11,369,567, previously published as PCT/IB2017/053348, filed on Jun. 7, 2017.
Claims priority of application No. 201621019719 (IN), filed on Jun. 8, 2016.
Prior Publication US 2022/0280421 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/40 (2006.01); A61K 47/10 (2017.01); A61K 47/38 (2006.01); A61K 47/02 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 47/24 (2006.01); A61K 47/14 (2017.01); A61K 47/40 (2006.01); A61K 9/10 (2006.01); A61K 31/366 (2006.01); A61K 31/505 (2006.01)
CPC A61K 9/0053 (2013.01) [A61K 9/0095 (2013.01); A61K 9/10 (2013.01); A61K 31/366 (2013.01); A61K 31/40 (2013.01); A61K 31/505 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61K 47/40 (2013.01)] 11 Claims
 
1. An aqueous suspension for oral administration, consisting of:
atorvastatin in an amount of about 0.4% w/w;
a suspending agent in an amount of about 2% w/w comprising carboxymethyl cellulose sodium in an amount of about 0.7% w/w and magnesium aluminum silicate in an amount of about 1.3% w/w;
a preservative in an amount of from 0.01% w/w to 0.5% w/w;
a sweetener in an amount of about 0.1% w/w to 2% w/w;
a flavoring agent in an amount of from 0.01 to 2.0% w/w;
and
a water vehicle;
wherein the atorvastatin has a d90 particle size of from 1 μm to 15 μm.